Article
Author(s):
Rotterdam, Netherlands-Four years is a reasonable interval for prostatecancer screening, concluded investigators from the European Randomized Studyof Screening for Prostate Cancer (ERSPC).
Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA
Key updates from the AUA/ASRM male infertility guideline amendment
Variants of unknown significance may adversely affect RARP outcomes
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
Genetic testing in prostate cancer is increasing over time, data suggests
Yale Urology’s First Female Professor